Synthesize Bio secures $10M in a Seed round led by Madrona to enhance generative genomics for drug development.

Sep 17, 2025•19 days ago

Amount Raised

$10 Million

Round Type

seed

SeattleBiotechnology

Investors

Ai2 IncubatorPoint Field PartnersInner Loop CapitalSahsen VenturesMadrona

Description

Synthesize Bio, a biotechnology firm, has announced a $10 million seed round led by Madrona, with participation from multiple investors. The funding aims to accelerate the development of its innovative generative genomics models. These models will assist biopharma companies in making informed drug development decisions. The GEM-1 foundation model is now available for use by biopharmaceutical companies and researchers.

Company Information

Company

Synthesize Bio

Location

Seattle, Washington, United States

About

Synthesize Bio is a biotechnology company pioneering biological foundation models to simulate the results of gene expression experiments. They develop generative genomics models that enable researchers to predict experimental outcomes and enhance drug development processes. Founded by experts in RNA informatics and translational data science, the company focuses on helping biopharmaceutical companies leverage rich data for faster, cost-effective decision-making.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends